Patent intelligence · US
US 11186590
Somatostatin modulators and uses thereof
Somatostatin modulators and uses thereof
Patent details — US 11186590
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 30, 2021
- Expiration
- Nov 25, 2041
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Claims
- 11
- CPC classes
- A61K, A61K47/14, A61K9/0014, A61K9/0019
Quick answer
US 11186590 (Somatostatin modulators and uses thereof) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Nov 30, 2021. Expires Nov 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K47/14, A61K9/0014, A61K9/0019, A61K9/0095, A61K9/06
More from CRINETICS PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12280046
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
granted -
US 12208092
Compositions and methods for administering paltusotine to patients with hepatic impairment
granted -
US 12134610
Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
granted -
US 11957674
Formulations of a somatostatin modulator
granted -
US 11834462
Somatostatin modulators and uses thereof
granted -
US 11773076
Crystalline forms of a somatostatin modulator
granted -
US 11608335
Somatostatin modulators and uses thereof
granted -
US 11566015
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
granted
Frequently asked questions
What is US patent 11186590?
US 11186590 (Somatostatin modulators and uses thereof) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Nov 30, 2021. Expires Nov 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11186590?
CRINETICS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 11186590 expire?
Our index shows an expiration date of Nov 25, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.